How to Integrate NON-Statin Therapy in Your Practice. Updates from the Latest 2022 LDL-Cholesterol Lowering Guidelines

How to Integrate NON-Statin Therapy in Your Practice. Updates from the Latest 2022 LDL-Cholesterol Lowering Guidelines

Guest: Regis I. Fernandes, M.D.

Hosts: Sharonne N. Hayes, M.D.

Since the last ACC/AHA cholesterol guidelines in 2018, the FDA has approved new non-statin cholesterol medications, which have increased our ability to provide a broader range of lipid-lowering drugs. In this podcast, we will discuss the new 2022 ACC expert consensus decision pathway on the role of non-statin therapies for LDL lowering in managing atherosclerotic cardiovascular disease risk. We will review these new drugs and discuss which ones to consider, when, and in what order.

 

Topics Discussed:

• What are these new FDA-approved nonstatin drugs for lipid-lowering?

• To whom and when non-statins should be considered?

• Are there new LDL targets or thresholds for certain patients?

• What are the new guideline recommendations for patients with statin intolerance?

 

Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices.

LinkedIn: Mayo Clinic Cardiovascular Services

Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today!

No CME credit offered for this episode.

Podcast episode transcript found here.